BIVI - BioVie, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
1.98 -0.05 (-2.51%)	---	---	0.0 (0.02%)	0.01 (0.54%)	-0.06 (-2.97%)	0.0 (0.0%)	0.0 (0.0%)

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -12.12
Diluted EPS:: -12.12
Basic P/E:: -0.1593
Diluted P/E:: -0.1593
RSI(14) 1m:: 0.0
VWAP:: 1.93
RVol:: 0.702

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	1.94 -0.02 (-1.02%)	Oct 15 13:15
1m	Price increase 1m	1.97 +0.02 (+1.24%)	Oct 15 12:10
1m	Price decrease 1m	1.97 -0.03 (-1.5%)	Oct 15 10:23
1m	Price decrease 1m	2.0 -0.04 (-1.96%)	Oct 15 10:18
10m	Price decrease 10m	2.0 -0.07 (-3.38%)	Oct 15 10:18